View Item 

Show simple item record

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study
dc.contributor.authorSeiwert, Tanguy Y.
dc.contributor.authorKochanny, Sara
dc.contributor.authorWood, Kevin
dc.contributor.authorWorden, Francis P.
dc.contributor.authorAdkins, Douglas
dc.contributor.authorWade, James L.
dc.contributor.authorSleckman, Bethany G.
dc.contributor.authorAnderson, Daniel
dc.contributor.authorBrisson, Ryan J.
dc.contributor.authorKarrison, Theodore
dc.contributor.authorStadler, Walter M.
dc.contributor.authorVokes, Everett E.
dc.date.accessioned2020-07-02T20:33:41Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-07-02T20:33:41Z
dc.date.issued2020-07-15
dc.identifier.citationSeiwert, Tanguy Y.; Kochanny, Sara; Wood, Kevin; Worden, Francis P.; Adkins, Douglas; Wade, James L.; Sleckman, Bethany G.; Anderson, Daniel; Brisson, Ryan J.; Karrison, Theodore; Stadler, Walter M.; Vokes, Everett E. (2020). "A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study." Cancer 126(14): 3237-3243.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/155947
dc.publisherWiley Periodicals, Inc.
dc.subject.othertemsirolimus
dc.subject.otherneoplasm recurrence
dc.subject.othersquamous cell carcinoma of head and neck
dc.subject.othertarget of rapamycin (TOR) serine‐threonine kinases
dc.subject.othercetuximab
dc.subject.othererbB‐1
dc.subject.otherlocal genes
dc.subject.otherneoplasm metastasis
dc.titleA randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155947/1/cncr32929_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155947/2/cncr32929.pdf
dc.identifier.doi10.1002/cncr.32929
dc.identifier.sourceCancer
dc.identifier.citedreferencede Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012; 18: 2336 ‐ 2343. doi: 10.1158/1078‐0432.CCR‐11‐2825
dc.identifier.citedreferenceCancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517: 576 ‐ 582.
dc.identifier.citedreferenceChung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006; 24: 4170 ‐ 4176.
dc.identifier.citedreferenceKimura H, Sakai K, Arao T, et al. Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor. Cancer Sci. 2007; 98: 1275 ‐ 1280.
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F, et al. Platinum‐based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116 ‐ 1127.
dc.identifier.citedreferenceSeiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014; 25: 1813 ‐ 1820.
dc.identifier.citedreferenceWheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944 ‐ 3956.
dc.identifier.citedreferenceAmornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN‐01. Clin Cancer Res. 2004; 10: 4029 ‐ 4037.
dc.identifier.citedreferenceNathan CO, Amirghahri N, Rice C, et al. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope. 2002; 112: 2129 ‐ 2140.
dc.identifier.citedreferenceBianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor–expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003; 22: 2812 ‐ 2822.
dc.identifier.citedreferenceWang Z, Martin D, Molinolo A, et al. mTOR co‐targeting in cetuximab resistance in head and neck cancers harboring PIK3CVA and RAS mutations. J Natl Cancer Inst. 2014; 106: dju215. doi: 10.1093/jnci/dju215
dc.identifier.citedreferenceJimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer. 2007; 96: 952 ‐ 959.
dc.identifier.citedreferenceBauman J, Arias‐Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum‐refractory head and neck squamous cell carcinoma. Oral Oncol. 2013; 49: 461 ‐ 467.
dc.identifier.citedreferenceMassarelli E, Lin H, Ginsberg LE, et al. Phase II trial of everolimus and erlotinib in patients with platinum‐resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015; 26: 1476 ‐ 1480.
dc.identifier.citedreferenceFury M, Lee NY, Sherman E, et al. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head‐and‐neck cancer. Int J Radiat Oncol Biol Phys. 2013; 87: 479 ‐ 486.
dc.identifier.citedreferenceSaba NJ, Hurwitz SJ, Magliocca K, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014; 120: 3940 ‐ 3951.
dc.identifier.citedreferenceLi SH, Lin WC, Huang TL, et al. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. Head Neck. 2016; 38 ( suppl 1 ): E844 ‐ E852.
dc.identifier.citedreferenceKaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457 ‐ 481.
dc.identifier.citedreferenceBrookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38: 29 ‐ 41.
dc.identifier.citedreferenceGeiger JL, Bauman JE, Gibson MK, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck. 2016; 38: 1759 ‐ 1764.
dc.identifier.citedreferenceBlaszczak W, Barczak W, Wegner A, et al. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. Med Oncol. 2017; 34: 60. doi: 10.1007/s12032‐017‐0918‐1
dc.identifier.citedreferenceEkshyyan O, Mills GM, Lian T, et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced‐stage head and neck squamous cell carcinoma. Head Neck. 2010; 32: 1619 ‐ 1628. doi: 10.1002/hed.21374
dc.identifier.citedreferenceHidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI‐779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res. 2006; 12: 5755 ‐ 5763. doi: 10.1158/1078‐0432.CCR‐06‐0118
dc.identifier.citedreferenceMachiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second‐line treatment in patients with recurrent or metastatic squamous‐cell carcinoma of the head and neck progressing on or after platinum‐based therapy (LUX‐Head & Neck 1): an open‐label, randomised phase 3 trial. Lancet Oncol. 2015; 16: 583 ‐ 594. doi: 10.1016/S1470‐2045(15)70124‐5
dc.identifier.citedreferenceCohen EEW, Licitra LF, Burtness B, et al. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second‐line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017; 71: 2526 ‐ 2532. doi: 10.1093/annonc/mdx344
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32929_am.pdf
Size:
329.9KB
Format:
PDF
View/Open
Name:
cncr32929.pdf
Size:
241.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.